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ABSTRACT: Store-operated calcium (Ca2+) entry is an important
homeostatic mechanism in cells, whereby the release of Ca2+ from
intracellular endoplasmic reticulum stores triggers the activation of a
Ca2+ influx pathway. Mediated by Orai1, this Ca2+ influx has specific
and essential roles in biological processes as diverse as lactation to
immunity. Although pharmacological inhibitors of this Ca2+ influx
mechanism have helped to define the role of store-operated Ca2+ entry
in many cellular events, the lack of isoform specific modulators and
activators of Orai1 has limited our full understanding of these processes.
Here we report the identification and synthesis of an Orai1 activity
enhancer that concurrently potentiated Orai1 Ca2+-dependent inactiva-
tion (CDI). This unique enhancer of Orai1 had only a modest effect on
Orai3 with weak inhibitory effects at high concentrations in intact
MCF-7 breast cancer cells. The Orai1 enhancer heightened vascular
smooth muscle cell migration induced by platelet-derived growth factor and the unique store-operated Ca2+ entry pathway present in
skeletal muscle cells. These studies show that IA65 is an exemplar for the translation and development of Orai isoform selective
agents. The ability of IA65 to activate CDI demonstrates that agents can be developed that can enhance Orai1-mediated Ca2+ influx
but avoid the cytotoxicity associated with sustained Orai1 activation. IA65 and/or future analogues with similar Orai1- and CDI-
activating properties could function to fine-tune physiological processes important in specific disease states, such as cellular migration
and immune cell function.
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Release of Ca2+ from the endoplasmic reticulum (ER) is akey event in cellular signaling pathways involving
activation of many G-protein coupled and tyrosine kinase
receptors. Activation of phospholipase C by these receptors
results in inositol 1,4,5-trisphosphate (IP3) generation and
depletion of ER Ca2+ stores.1 Calcium-release-activated
calcium (CRAC) channels, which are made up of hexamers
of the protein Orai1, are responsible for the influx of Ca2+ after
receptor-mediated depletion of ER Ca2+ stores.2−4 This
canonical pathway is termed store-operated Ca2+ entry
(SOCE) and involves the activation of Orai1 channels by
the ER Ca2+ store sensor STIM1.5−7
The consequence of the absence or loss of function of Orai1
is manifested in humans by a severe combined immune-
deficiency (SCID)-like condition, autoimmunity, anhidrosis
(inability to sweat normally), tooth enamel defects, and
generalized muscle weakness.5,8 A variety of studies have now
provided clear mechanistic insights into the critical role for
Orai1-mediated Ca2+ influx in a variety of physiological
processes as diverse as T-cell mediated immunity, lactation,
and gene transcription.9−11 The aberrant expression or activity
of Orai1 in disease models has seen pharmacological
modulators of CRAC currently postulated as therapies for a
diverse set of conditions such as inflammatory bowel disease,
asthma, psoriasis, and cancer.12,13 Indeed, assessment of
pharmacological inhibitors of CRAC in mouse in vivo models
has shown their ability to protect against acute pancreatitis14
and breast cancer metastasis.15 The commencement of clinical
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trials of CRAC inhibitors for acute pancreatitis, relapsed or
refractory non-Hodgkin’s lymphoma, and psoriasis are
reflective of the pharmacotherapy opportunities for this class
of agents.12
Our full understanding of Orai1, however, has been limited
by the delay in the development of pharmacological activators
of Orai1-mediated Ca2+ influx. Pharmacological activators have
proven to be powerful tools to define the role of other Ca2+-
permeable ion channels in cellular processes and as potential
therapeutic targets. Such agents include activators of TRPV1
(capsaicin), TRPV4 (GSK1016790A) and L-type Ca2+
channels ((S)-(−)-BAY K 8644). Although Orai3 but not
Orai1 can be activated by 50 μM 2-aminoethyldiphenyl
borinate (2-APB),16 2-APB is a largely nonselective tool that
has been shown to affect a plethora of ion channels with
distinct structures and subcellular locations.17 Thus, pharma-
cological tools necessary to fully probe the consequences of
Orai1 activation are currently lacking. Given the coexpression
of Orai isoforms in many cell types, such as in MCF-7 breast
cancer cells where both Orai1 and Orai3 can function as store-
operated Ca2+ channels,18 some selectivity for Orai1 over
Orai3 is critical. Sustained pharmacological activation of Orai1
may be detrimental, given that Orai1 gain of function
mutations result in muscle cramping, muscle stiffness, limited
joint movement, persistent pupil constriction, ichthyosis (dry,
thick, and scaly skin), and dyslexia19 and because of the role of
Orai1 in cell death associated with acute pancreatitis.14 Hence,
compounds that enhance Orai1 activity triggered by store
depletion while concomitantly promoting Orai1 calcium-
dependent inactivation (CDI)20 and exhibiting some selectiv-
ity over Orai3 may allow promotion of near-physiological
Orai1-mediated Ca2+ entry during key events without either
inducing cytotoxicity from Ca2+ overload or triggering Orai3-
dependent pathways. CDI has been recently shown to be
critical in defining the nature of cytosolic free Ca2+ ([Ca2+]CYT)
transients and the regulation of the Ca2+-dependent tran-
scription factor nuclear factor of activated T-cells (NFAT).21
Riva et al.22 very recently reported a family of pyrtriazoles that
included agents that act as SOCE inhibitors or activators or
enhancers; however, activation effects were modest and Orai3
selectivity and effects on CDI were not defined.
Here, we identify and characterize a new pharmacological
tool for the selective enhancement of Orai1-mediated Ca2+
influx. This agent, which we termed IA65, enhances Orai1
activity with concurrent enhancement of Orai1 CDI and little
effect on Orai3. We use this new tool to provide new insights
into the role of Orai1 in smooth and skeletal muscles.
■ RESULTS
During an assessment of a library of over 2100 small-molecule
compounds from ChemBridge as potential inhibitors of SOCE
in MDA-MB-231 breast cancer cells, where SOCE is mediated
by Orai1,23,24 one benzoic acid was identified as a promotor of
SOCE. 4-((5-Phenyl-4-(trifluoromethyl)thiazol-2-yl)amino)-
benzoic acid (IA65, Figure 1A) had no effect on the Ca2+
release from ER Ca2+ stores via the sarco-/ER Ca2+-ATPase
(SERCA) inhibitor cyclopiazonic acid (CPA). However, unlike
previously described modulators of SOCE,24−26 IA65
augmented rather than inhibited the Ca2+ influx induced by
ER Ca2+ store depletion with an EC50 of ∼1.9 μM (Figure
1B,C). Analogues of IA65 exhibit either more modest (e.g., 19)
or no promotion (e.g., 1) or even modest inhibition (e.g., 17)
of SOCE (Table S1). IA65 did not show any activity (neither
inhibition nor activation) against TRPV1, TRPM8, or CaV2.2
Figure 1. IA65 promotes Orai1-mediated Ca2+ influx. (A) Chemical structure of IA65. (B) Mean [Ca2+]CYT levels during assessment of SOCE in
MDA-MB-231 cells treated with increasing concentrations of IA65. Cells were pretreated with IA65 for 15 min at room temperature, and IA65
concentrations were maintained during an assessment of SOCE. (C) Intracellular Ca2+ measurements as area under curve (AUC) calculated during
SOCE Ca2+ influx, after treatment of cells with vehicle control or increasing concentrations of IA65 (30 nM to 30 μM) in MDA-MB-231 cells. n =
3, mean ± SD.
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at concentrations up to 100 μM (Table S2). IA65 also did not
cause any toxicity in MDA-MB-231 cells at concentrations up
to 100 μM (Figure S1).
To define the mechanisms of IA65 action on SOCE, we
exploited the phenomena in estrogen-receptor-positive MCF-7
breast cancer cells whereby SOCE is mediated by both Orai1
and Orai3.18 Consistent with results in MDA-MB-231 breast
cancer cells, in wild type MCF-7 breast cancer cells, IA65
promoted SOCE with significant augmentation of Ca2+ influx
at 1 μM with no effects on Ca2+ release induced by CPA at any
assessed concentration (Figure 2A−D). In contrast, in MCF-7
cells with CRISPR-mediated knockout of Orai1 (Orai1 KO),
no promotion of SOCE was observed at any concertation of
IA65 assessed (Figure 2E−H). Instead, IA65 significantly
Figure 2. IA65 activates native Orai1, but not Orai3-mediated SOCE in MCF-7 cells. Mean [Ca2+]CYT levels and quantitative analysis during
assessment of SOCE in (A−D) MCF7-WT and (E−H) MCF7-Orai1 KO cells. Cells were pretreated with IA65 for 15 min at room temperature
and IA65 concentrations were maintained during assessment of SOCE. ns = not significant (p > 0.05); *, p < 0.05; **, p < 0.01; and ****, p <
0.0001 (one-way ANOVA, with Dunnett’s multiple comparisons). n = 3, mean ± SD.
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reduced SOCE at the higher concentrations of 3 and 10 μM in
MCF-7 Orai1 KO cells, suggesting a possible effect on Orai3
under these conditions, given that Orai3 mediates SOCE in
MCF-7 cells. The protocols and guide RNAs used for Orai1
knockout in MCF7 cells are listed in the Materials and
Methods. Orai1 knockdown in MCF7 cells was documented
Figure 3. IA65 enhanced Orai1 ICRAC. (A) Whole-cell patch clamp recording in Orai1/2/3 triple-knockout HEK293 cells expressing STIM1 along
with Orai1 shows that Orai1-mediated CRAC current is enhanced by 10 μM IA65 and blocked by 5 μM Gd3+. (B) Representative I−V curves on
current traces taken where indicated by the color-coded asterisks. (C) Current densities. (D) Whole-cell patch clamp recording in Orai1/2/3 triple-
knockout HEK293 cells coexpressing STIM1 and Orai3 shows that Orai3-mediated CRAC current are not as affected by application of 10 μM
IA65, but are blocked by 5 μM Gd3+, as expected. (E) Representative I−V relationships. (F) Current densities. (G) Comparison of the magnitude
of enhancement of Orai1 and Orai3 CRAC currents by IA65 shows significantly greater enhancement of Orai1 compared to Orai3. Data were
statistically analyzed using a paired sample t test and represented as mean ± SEM (*, p < 0.05; **, p < 0.01). Pair-sample t-test was used for panels
C and F; two-sample t-test was used for panel G.
Figure 4. Effect of IA65 on CDI from Orai1 and Orai3 channels. Representative currents were recorded from Orai1/2/3 triple-knockout HEK293
cells coexpressing STIM1 and Orai1. EGTA (10 mM) in the patch pipet was used to cause store depletion, and ICRAC was recorded in the presence
of either (A) vehicle control or (B) IA65 at 10 μM in the bath solution. (C) For quantification of CDI, the extent of inactivation at 146 ms, the
residual current remaining at the end of the test pulse (at 146 ms) relative to the peak current at 3 ms was plotted against test potential. (D and E)
Representative currents assessing CDI under the same protocol were recorded from Orai1/2/3 triple-knockout HEK293 cells coexpressing STIM1
and Orai3. (F) For quantification of CDI, the extent of inactivation at 146 ms, the residual current remaining at the end of the test pulse (at 146
ms) relative to the peak current at 3 ms was plotted against test potential. ***, p < 0.001; two-tailed Student’s t test was used for panels C and F.
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by genome sequencing and by Western blotting using an
Orai1-specific antibody (Figure S2).
To directly assess the effect of IA65 on Orai1-mediated
CRAC currents (ICRAC), ICRAC recordings in HEK293 cells
coexpressing STIM1 with either Orai1 or Orai3 using the
weaker more physiological chelator EGTA to deplete stores
were conducted. This showed that preincubation of cells with
IA65 at either 3 or 10 μM caused concentration-dependent
potentiation of Orai1-mediated currents with no effect on
Orai3-mediated currents (Figures S3 and S4), consistent with
SOCE effects in intact MCF-7 breast cancer cell lines (Figure
2).
We then assessed the effect of IA65 on Orai1 and Orai3
coexpressed with their protein activator, the ER Ca2+ sensor
STIM1, in HEK293 cells lacking all three Orai isoforms (Orai
triple-knockout; Orai-TKO). Protocols and specific guide
RNAs (gRNAs) used for the generation of Orai-TKO cells
are listed in the Materials and Methods. We used two
independent gRNA flanking each Orai gene to completely
excise the gene, allowing us to use the total loss of mRNA (as
assessed by RT-qPCR) as a reliable means for documenting
knockout. The use of this strategy is critical for knockout of
Orai2 and Orai3, for which no reliable antibodies currently
exist. In addition to genome sequencing, RT-qPCR for Orai2
and Orai3 isoforms and Western blots for Orai1 were used to
document knockout (Figure S5). In these recordings, we used
20 mM of the fast buffer BAPTA to deplete the ER Ca2+ stores
while preventing Ca2+-dependent inhibition (CDI) of Orai
channels driven by rises in [Ca2+]CYT. Under these conditions,
10 μM IA65 enhanced ICRAC mediated by Orai1 (Figure 3A−
C). This enhancement of Orai1 ICRAC by IA65 was abolished
by the ICRAC inhibitor gadolinium (Gd
3+) at the low
concentration of 5 μM (Figure 3A−C). Despite strong
cytosolic Ca2+ buffering with BAPTA to abrogate CDI, ICRAC
measurements using the same protocol in Orai-TKO HEK293
cells coexpressing Orai3 and STIM1 showed only slight
potentiation of Orai3 ICRAC by IA65, providing further
evidence that IA65 (10 μM) is only a marginal Orai3 regulator
under highly permissive “non-physiological” conditions (Figure
3D−F). Indeed, the enhancement of Orai1 was significantly
greater than for Orai3 (Figure 3G). Further assessment also
identified that IA65 had a unique ability to also enhance Orai1
but not Orai3 CDI (which was inhibited) (Figure 4A−F),
suggesting that it may be possible to fine-tune Orai1-mediated
Ca2+ signaling and avoid the deleterious effects of sustained
Orai1 activation.
We then performed concentration−response analysis of
IA65 (at 1, 3, and 10 μM) on CDI of Orai1 and Orai3
coexpressed with STIM in Orai-TKO HEK293 cells using 10
mM EGTA in the patch pipet. The results depicted in Figure
S6 show that IA65 enhanced CDI of Orai1 in a concentration-
dependent manner while inhibiting CDI of Orai3. Similar
recordings of Orai1 CDI in Orai-TKO cells coexpressing Orai1
and STIM1 and using 20 mM of the strong buffer BAPTA in
Figure 5. IA65 promotes vascular smooth muscle cell (VSMC) migration. (A) VSMC showed significant proliferation in response to IA65 (0.5 and
3 μM) at 48 and 72 h compared to 0 ng/mL PDGF control. Maximal concentrations of PDGF (10 ng/mL) were used as a positive control. (B)
Both 0.5 and 3 μM IA65 did not synergize with low concentrations of PDGF (0.5 ng/mL) in VSMC proliferation. (C) A dose of 0.5 μM IA65 did
not induce significant VSMC migration at 12 h but showed a synergistic effect on VSMC migration when added with a low concentration of PDGF
(0.5 ng/mL), comparable to maximal concentrations of PDGF (10 ng/mL). (D) Representative bright-field images of gap-closure experiments.
Scale bar equals 500 μm. ANOVA and Dunnett’s multiple comparison test were used for proliferation and migration experiments. *, p < 0.05; **, p
< 0.01; ***, p < 0.001; and ****, p < 0.0001 when compared to 0 ng/mL of PDGF. #, p < 0.05, and ##, p < 0.01, when compared to 0.5 ng/mL of
PDGF.
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the patch pipet to elicit ICRAC clearly showed that IA65
enhancement of Orai1 CDI is maintained in the presence of
BAPTA, suggesting that the effect of IA65 is at least partially
Ca2+-independent (Figure S7). Indeed, we performed similar
Orai1 CDI recordings on the same cells and under the same
intracellular buffering conditions, except that 20 mM
extracellular Ca2+ was now substituted with 20 mM Ba2+. In
the presence of 20 mM extracellular Ba2+, Orai1 CDI was
apparent only when IA65 was added to the bath solution and
the tail current was reduced, a strong argument for the effect of
IA65 on Orai1 CDI being at least partially Ca2+-independent
(Figure S8).
The evaluation of the physiological consequences of Orai1-
mediated Ca2+ influx enhancement and promotion of CDI was
assessed in the context of vascular smooth muscle cell (VSMC)
proliferation and migration. As expected, the maximal
concentration of the platelet-derived growth factor (PDGF;
10 ng/mL) produced a pronounced stimulation of prolifer-
ation with low concentrations of IA65 (0.5 or 3 μM)
producing only a modest effect (Figure 5A). Furthermore,
IA65 did not enhance the pro-proliferative effects of a
submaximal concentration of PDGF (0.5 ng/mL) (Figure
5B), suggesting that the effects of submaximal concentrations
of IA65 and PDGF on VSMC proliferation are not additive. In
contrast, consistent with the reported role of Orai1 in
migration in a variety of cell types,27−31 IA65 significantly
enhanced the ability of submaximal concentrations of PDGF to
enhance the migration of VSMCs (Figure 5C,D). The ability
of IA65 to augment rather than suppress migration of VSMCs
was also consistent with a lack of cytotoxicity of IA65 at
concentrations that promoted SOCE (Figure S1).
To assess the effect of IA65 on Orai1-mediated Ca2+ entry in
skeletal muscle, mechanically skinned fibers from rat extensor
digitorum longus (EDL) muscles were used. A Ca2+-sensitive
dye (rhod-5N) was trapped in the tubular (t-)system and used
to monitor Ca2+ movements across the t-system membrane.32
By tracking the t-system [Ca2+] ([Ca2+]t‑sys) transient, SOCE
activity and thus Orai1 activity can be tracked (Figure 6A−C).
The experiment in Figure 6D shows [Ca2+]t‑sys transient
initially in the presence of a resting cytoplasmic solution with
200 nM [Ca2+]cyto. In this solution the [Ca
2+]t‑sys displays a
steady level of around 1 mM. The substitution of this solution
for 30 mM caffeine in the presence of 0.01 mM [Mg2+]cyto
causes a rapid release of Ca2+ from the sarcoplasmic reticulum
(SR) and a rapid activation of SOCE and a depletion of
[Ca2+]t‑sys to approximately 0.05 mM.
32−36 Exchange of the
caffeine solution for the resting solution with 200 nM
[Ca2+]cyto allows the [Ca
2+]t‑sys to reach mM levels again.
From the same [Ca2+]t‑sys (and therefore the same driving force
for Ca2+ entry, DFCa), the effect of a solution containing 0.4
Figure 6. Effect of IA65 on t-system calcium movements. Schematic representation of the steps of loading dye into the t-system, to track [Ca2+]t‑sys
transients. (A) Intact rat fiber in standard physiological solution (yellow). (B) A physiological solution containing rhod-5N (red) is introduced to
the intact fiber, allowing the dye to diffuse into the t-system. (C) The fiber is mechanically skinned with fine forceps, which causes the t-system to
seal at the former interface between the outer plasma membrane and the t-system and trap the dye in the extracellular space (t-system). (D)
Spatially averaged t-system Rhod-5N signal during a series of solution exchanges from resting solution, where [Ca2+]t‑sys reaches a steady state in
the mM range, to fully (caffeine 30 mM, Ca2+ 0 mM, Mg2+ 0.01 mM) or partially (Ca2+ 0 mM, Mg2+ 0.4 mM with and without 10 μM IA65)
activate SOCE (shown in black). The t-system Ca2+ flux was derived from [Ca2+]t‑sys (shown in red). (E) The t-system Ca
2+ concentration after the
different Orai1 activation conditions. (F) Peak t-system Ca2+efflux induced by the different Orai1 activation conditions. Data was compared by one-
way ANOVA with Tukey’s post hoc test (*, p < 0.05). N = 6−8.
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mM [Mg2+]cyto and no added Ca
2+ was applied to observe the
effect of a submaximal increases in the activity of the ryanodine
receptor (RyR) on the rate of Orai1-dependent Ca2+ entry. In
this solution, the [Ca2+]t‑sys transient declined, but more slowly
than it did in the presence of caffeine. Note that caffeine and
low [Mg2+]cyto activate the RyR without changing the resting
membrane potential of the t-system, so that no voltage-
activated Ca2+ fluxes interfere with the tracking of store-
dependent Ca2+ fluxes across the t-system in these experi-
ments.
The submaximal activation of SOCE in 0.4 mM [Mg2+]cyto
provided a means to determine whether IA65 accelerated the
rate of Ca2+ entry through Orai1. The application of 0.4 mM
[Mg2+]cyto, no added Ca
2+, and 10 μM IA65 to the fiber with
an initial [Ca2+]t‑sys close to 1 mM caused a more rapid decline
than in the same solution in the absence of IA65. Figure 6E
shows the steady-state nadirs achieved in RyR-activating
solutions that trigger SOCE. Maximal SOCE in caffeine
reduced [Ca2+]t‑sys to the lowest level. Figure 6F presents the
rate at which the [Ca2+]t‑sys transient declined during SOCE in
the presence of caffeine, 0.4 mM [Mg2+]t‑sys in the absence and
presence of IA65. IA65 significantly increased the rate of Orai1
activation compared to its absence for the same degree of
activation of RyR Ca2+ conductance.33
■ DISCUSSION
While there is continuing development of inhibitors of SOCE,
with four compounds (CM2489 and CM 4620 from
CalciMedica; RP2128 and RP4010 from Rhizen Pharmaceut-
icals) reported to have entered clinical trials for various
indications,22 there is also a rising interest in the development
of stimulators. These include the mineralocorticoid desoxy-
corticosterone acetate,37 the borinate MDEB,38 and some
examples of the new class of pyrtriazoles,22 but the selectivity
of these compounds is not known.
The identification of 4-((5-phenyl-4-(trifluoromethyl)-
thiazol-2-yl)amino)benzoic acid (IA65) as an enhancer of
SOCE, despite our original aim to identify SOCE inhibitors,
supports the idea that minor structural modifications of ion
channel inhibitors can produce ion channel activators. This is
exemplified by the ability of different enantiomers of
BAYK8644 to produce activation or inhibition of L-type
voltage-gated Ca2+ channels.39 More specifically, the struc-
ture−activity relationships within the set of compounds
assessed in this study suggests that the carboxylic acid is
essential for activation of Orai1, as is its positioning para
(opposite) to the central aminothiazole unit; compounds 6−9,
with a meta-positioned acid, were inactive. A second
requirement is that the bulky aromatic substituent is appended
to the 5-position of the aminothiazole (adjacent to the sulfur),
which gives the molecule a reasonably linear shape. This is
consistent with the putative protein-binding site being a
narrow tubular or groove-shaped one with a cationic group at
one end and a lipophilic region at the other. An H-bond donor
and an acceptor on opposite sides in the center of the site
could also accept an H-bond from the aminothiazole NH and
donate one to the thiazole ring nitrogen (Figure S9).
The ability of IA65 to enhance Orai1 but not Orai3 activity
places this agent as one of the most selective agents to explore
Orai1-mediated SOCE in cellular signaling processes and
biological events so far developed. Pharmacological modulators
of SOCE have historically lacked selectivity with pronounced
effects across diverse ion channel families. This is exemplified
by the actions of the SOCE inhibitors Gd3+, SKF96365, and 2-
APB which act on a number of Ca2+-permeable ion channels.40
Even more recently described Orai1 inhibitors such as GSK-
7975A, GSK-5503A, and Synta66 also have been reported to
have similar inhibitory effects on Orai3.41 The action of these
agents appears to be independent of direct effects on STIM1
binding to Orai1 or to changes in the oligomerization of
STIM1. These agents have been suggested instead to act via an
allosteric effect on the selectivity filter of Orai channels.41
The mammalian Orai ion channels Orai1, Orai2, and Orai3
consist of hexamers formed by four-transmembrane subunits
that assemble around a central Ca2+-permeable pore. Orai3 is
believed to have evolved from Orai1;42 Orai3 has an extended
N-terminus as well as truncations in the extracellular loop
between transmembrane domain 3 and 4 and the C-terminus
in Orai3 relative to Orai1. Given this divergence in primary
structure, it is difficult to identify likely regions contributing to
the observed functional selectivity of IA65. However, given the
importance of the N-terminal domain of Orai1 in channel
activation and CDI, this region may be contributing to
activation of Orai1 by IA65. The pronounced differential
effects of IA65 on Orai1 and Orai3 may indicate that this
moiety could be a scaffold to achieve Orai1 inhibitors with
improved selectivity over Orai3. At the very least, IA65 defines
the opportunity for selective modulation of Orai isoforms,
which will be critical to future studies of SOCE and/or the
development of Orai1 pharmacological modulators that have
less side effects due to a lack of effects on Orai3. Our
identification of differential modulation of Orai1 and Orai3 by
IA65 also suggests that selective Orai3 pharmacological
inhibitors might be achievable. This may be of particular
significance given the identification of Orai3 associated
processes are important in disease states such as in the growth
of estrogen receptor positive breast cancers.43
The studies presented here have also demonstrated the
ability of enhancement of Orai1-mediated Ca2+ influx to
influence physiological processes. Specifically, our studies with
IA65 show that enhancement of the SOCE induced by PDGF
is sufficient to promote the migration but not proliferation of
VSMCs, suggesting that IA65 can be used to specifically fine-
tune a cellular function.
Skeletal muscle possesses a unique presentation of SOCE,
where it is rapidly activated in response to increases in RyR
activity.44 In our experiments where we could track the flux of
Ca2+ through the Orai1 channel during the increased activity of
the RyR, IA65 increased the rate of Ca2+ flux through Orai1.
An increase in Orai1 Ca2+ flux was observed during a
submaximal activation of the RyR. Our results in skeletal
muscle fibers are consistent with IA65 enhancing the
conductance of Ca2+ through Orai1 under conditions where
SOCE is already partially activated.
In addition to IA65 as an exemplar for the potential for the
development of more Orai isoform selective agents, IA65 and/
or future analogues with similar CDI-activating properties may
be useful in defining or even controlling a variety of
physiological processes important in disease. For example,
Orai1 activators can be used to enhance vascular smooth
muscle migration to promote wound healing or to boost T-
and B-cell immune function.
Gain-of-function mutations in Orai1 cause tubular aggregate
myopathy (TAM), a condition caused by excessive store-
dependent Ca2+ influx in skeletal muscle (and can also present
with a mutation in STIM1 or the SR Ca2+-buffer,
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calsequestrin).19 How the enhanced activation of Orai1-
dependent Ca2+ entry leads to the characteristic tubular
aggregates and muscle weakness that define the disease
phenotype still remains to be elucidated. IA65 will provide a
valuable tool as an Orai1 enhancer to examine Orai1-related
myopathy. IA65 will provide insights into Orai1 gain-of-
function TAM by providing a means of acutely accelerating
Ca2+ entry into healthy muscle fibers.
These studies demonstrate the ability for pharmacological
agents to selectively and differentially modulate Orai channel
isoforms. The development of an Orai1 activity enhancer with
concurrent activation of CDI has allowed the identification of a
selective role for Orai1-mediated SOCE in the promotion of
PDGF-induced migration of VSMCs and the role of Orai1 in
Ca2+ homeostasis in skeletal muscle. This new tool will allow
further assessment of these and other Orai1-regulated
processes in different cell types such as neurons, glial cells,
and lymphocytes without the potential cytotoxic effects of
sustained Orai1 activation.
■ MATERIALS AND METHODS
Chemicals and Synthesis of the Orai1 Enhancer 4-((5-
Phenyl-4-(trifluoromethyl)thiazol-2-yl)amino)benzoic
acid (IA65). Compounds 1−20 including IA65 used for initial
testing were obtained from ChemBridge Corporation (San
Diego, CA). For the synthesis of larger amounts of IA65, 3-
bromo-1,1,1-trifluoro-3-phenylpropan-2-one was first prepared
whereby a solution of bromine (200 mg, 1.28 mmol) in
trifluoromethylbenzene (1 mL) was added dropwise to a
solution of 1,1,1-trifluoro-3-phenylpropan-2-one (200 mg, 1.06
mmol) in trifluoromethylbenzene (3 mL). The solution was
stirred and irradiated with a 200 W lamp for 2 h. The solution
was then diluted with EtOAc, washed with cold 1% sodium
disulfite and water, and dried (Na2SO4). Vacuum flash
chromatography (petroleum ether/diethyl ether; 100:0 to
12:5) gave 3-bromo-1,1,1-trifluoro-3-phenylpropan-2-one45
(150 mg, 54%) as an unstable wax; LR-LCMS M − 1 265/
267. The product was kept at −20 °C until required. For the
synthesis of 4-((5-phenyl-4-(trifluoromethyl)thiazol-2-yl)-
amino)benzoic acid (IA65), a solution of 3-bromo-1,1,1-
trifluoro-3-phenylpropan-2-one (125 mg, 46.8 mmol) and 4-
thioureidobenzoic acid (92 mg, 46.8 mmol) in dioxane (10
mL) was heated at 70 °C for 3 days. Solvents were removed,
and the residue was triturated with petroleum ether and diethyl
ether to yield 4-((5-phenyl-4-(trifluoromethyl)thiazol-2-yl)-
amino)benzoic acid46 (115 mg, 68%) as a white solid; mp
272−275 °C. 1H NMR [(CD3)2SO] δ 12.65 (broad s, 1H),
10.99 (s, 1H), 7.93 (d, J = 8.8 Hz, 2H), 7.69 (d, J = 8.8 Hz,
2H), 7.54−7.45 (m, 5H). HRMS: found M + 1 = 365.0568,
calculated M + 1 = 365.0564. HPLC purity: 98.9%.
The identities of compounds 1−20 and IA65 were examined
by high-resolution mass spectrometry using an Agilent 6520
Accurate-Mass Q-TOF LC/MS system operating in positive
electrospray ionization mode. A 10 μL aliquot of a 10 μM
solution of compound in HPLC-grade methanol was injected
into the instrument using an Agilent 1290 HPLC system with
column bypass and the observed masses of all compounds were
within 5 ppm of the calculated values.
Cell Culture. The MDA-MB-231 cell line was obtained
from The American Type Culture Collection (ATCC,
Manassas, VA) and maintained in Dulbecco’s modified Eagle’s
medium (DMEM) with high glucose (Sigma-Aldrich, St
Louise, MO), supplemented with 4 mM L-glutamine and
10% fetal bovine serum (FBS). The MCF7-WT cell line was
obtained from ATCC. MCF7-Orai1 KO cells were generated
by the Trebak laboratory by using the CRISPR/Cas9
technique. All MCF7 cells are cultured as described for
MDA-MB-231 cells.
Orai1/2/3 triple-knockout HEK293 cell line was generated
by the Trebak laboratory by using CRISPR/Cas9 technique as
described below. STIM1 and Orai1 stable HEK293 cells are a
generous gift from Donald L. Gill (Penn State University). All
HEK293 cells are maintained in DMEM with high glucose
(ThermoFisher Scientific, Waltham, MA), 10% FBS, and 1%
antibiotic−antimycotic.
For vascular smooth muscle cell (VSMC) culture, all
experiments using rats were reviewed and approved by the
Institutional Animal Care and Use Committee at Pennsylvania
State University College of Medicine. Adult male rats (200−
300 g) were euthanized, and thoracic aortas were dissected and
placed in ice-cold physiological saline solution. Adventitial and
intimal layers were microdissected from the aorta. Medial
layers of the aorta were diced into small pieces and placed in
an enzyme solution of type II collagenase, elastase, and
soybean trypsin inhibitor (Worthington Biochemical) for 60
min at 37 °C with constant agitation. The enzyme solution was
removed, and VSMCs were filtered through a 100 μm cell
strainer. VSMCs were seeded onto tissue culture plates and
further cultured using 45% DMEM and 45% Ham’s F-12
media supplemented with 10% FBS, 1% L-glutamine, and 1%
antibiotic−antimycotic at 37 °C, 5% CO2, and 100% humidity.
All VSMC experiments used cells between passages 3 and 8.
Generation of Triple-Knockout Orai Channel Iso-
forms in HEK293 Cells and Single-Knockout Orai1 in
MCF7 Cells Using CRISPR/Cas9. Orai1 gene knockout was
performed as previously described.21 Briefly, for Orai1 gene
knockout, a single Orai1-specific gRNA (5′-GTTGCTCACC-
GCCTCGATGT-3′) was subcloned into the lentiCRISPR v2
vector (Addgene, Plasmid #52961) to generate insertion/
deletions within the Orai1 gene. Wildtype HEK293 or wildtype
MCF7 cells were transfected with the corresponding Orai1-
targeting vector using nucleofection. Two days after trans-
fection, puromycin (2 μg/mL) (Gemini Bio Products, West
Sacramento, CA) was added to the medium to select for cells
expressing the lentiCRISPR v2 vector. At 6 days after
puromycin selection, cells were collected and seeded at a
density of 1 cell/well into 96-well plates. Once colonies had
formed clones were screened using the Guide-it Mutation
Detection Kit (Clontech Laboratories, 631443) and genetic
knockout confirmed by Sanger-sequencing as follows. The
Orai1 guide RNA is targeted to make a cut in the human Orai1
coding sequence between nucleotides 635 and 636. Sanger
sequencing showed that in our clone of Orai1-KO HEK293,
the first allele showed a 23 nucleotide deletion from
nucleotides 618 to 640. The second allele has a 16 nucleotide
insertion at the cut site (nucleotide 635). Both changes result
in a frameshift mutation and the formation of a premature stop
codon. Total Orai1 knockout was further confirmed by
Western blots. For the Orai1-KO MCF7 cells, each allele
was also altered in a different manner. The first allele showed a
single nucleotide deletion at position 635, while the second
allele has a 65 nucleotide deletion that spans from nucleotide
583 to 647. Both deletions caused frameshift mutations and an
early stop codon. Total Orai1 knockout in MCF7 cells was
further confirmed by Western blots.
ACS Pharmacology & Translational Science pubs.acs.org/ptsci Article
https://dx.doi.org/10.1021/acsptsci.9b00081
ACS Pharmacol. Transl. Sci. 2020, 3, 135−147
142
We then used these Orai1 knockout HEK293 cells to
generate double Orai1/Orai2 and subsequently triple Orai1/
Orai2/Orai3 knockout cells. Due to the lack of specific Orai2
and Orai3 antibodies required to document absence of protein
expression, we adapted a different CRISPR/Cas9 method
aimed at achieving complete genomic deletion of Orai2 and
Orai3 in single-knockout Orai1 clones. This allows for the use
of a complete loss of mRNA in RT-qPCR assays as reliable
means of establishing gene knockout. We subcloned two Orai2
(5′-ACGACAGGGCCTGTACCGAG-3′ and 5′-CTCAT-
GCGGGGACTCGCTGA-3′) or two Orai3 (5′-GTTCG-
TGCACCGCGGCTACC-3′ and 5′-CCAGAGACTG-
CACCGCTACG-3′) specific gRNAs flanking the entire
Orai2 or Orai3 gene into two fluorescent vectors (pSpCas9-
(BB)-2A-GFP and pU6-(BbsI)_CBh-Cas9-T2A-mCherry:
Addgene). At 24 h after transfection, single cells with high
expression of GFP and mCherry were sorted into 96-well
plates (FACS Aria SORP high-performance cell sorter). Cells
were then maintained in complete medium until colonies
began to form. Visible colonies were collected, DNA extracted,
and screened using specific primers designed to resolve a
wildtype or knockout PCR product. Positive clones were
chosen when only the knockout band was seen with no
product in the wildtype reaction. The complete list of primers
can be found in Table S3.
Western Blotting. Lysates were prepared using RIPA lysis
buffer (Sigma) supplemented with protease inhibitors
(Thermofisher Scientific). Both 30 and 50 μg samples of
protein lysate were used for experiments with HEK293 and
MCF7 cells, respectively. Protein was loaded into a 4−12%
Bis-Tris gel (Life Technologies) and then transferred onto a
PVDF membrane (Millipore). After blocking for 1 h at room
temperature with Olympus Blocking Buffer (LI-COR),
membranes were incubated for 2 h at room temperature
with primary antibody diluted in Olympus Blocking Buffer and
0.1% Tween. The dilutions of primary antibodies were as
follows: rabbit anti-ORAI1 (Sigma) 1:1000, mouse anti-
HSP70 (Santa Cruz) 1:4000, mouse anti-GAPDH (Millipore)
1:3000, and mouse anti-α-tubulin (CST) 1:2000. Following
four washes with 0.1% TBST for 5 min each, membranes were
placed in secondary antibody diluted in Olympus Blocking
Buffer and 0.1% Tween for 1 h at room temperature. The
secondary antibodies were 1:10 000 680RD conjugated anti-
mouse (LI-COR) and 1:5000 800CW conjugated anti-rabbit
(LI-COR). After four further washes with 0.1% TBST for 5
min each, images of blots were taken using the Odyssey Clx
imaging system. Densitometry was quantified using Image-
Studio Lite.
Quantitative PCR. Using RNAeasy Minikit (Qiagen) total
RNA was isolated from HEK293 cells and quantified using
nanodrop 2000 spectrophotometer (Thermofisher Scientific).
A 1 μg sample of total RNA was transcribed into cDNA using
the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). In a 96-well plate, cDNA was loaded along with
SYBR Green qPCR Master Mix (Applied Biosystems) and
corresponding primers (Table 1). Target mRNA expression
was then collected and quantified using the QuantStudio 3
real-time PCR system (Applied Biosystems) with the PCR
protocol as follows: 50 °C 2 min activation step, a 95 °C 2 min
melt step, 40 cycles of 95 °C for 15 s followed by 54.3 °C for
15 s and 72 °C for 30 s. To validate primer specificity, a melt
curve was generated. Target mRNA expression was quantified
by comparative ΔCt method and normalized to the house-
keeping genes GAPDH and NONO. All qPCR experiments
were performed in technical triplicates and biological
duplicates.
[Ca2+]CYT Assays in Breast Cancer Cells. Assessment of
cytosolic free Ca2+ ([Ca2+]CYT) was performed using a
Fluorometric Imaging Plate Reader (FLIPRTETRA, Molecular
Devices) and PBX no-wash Ca2+ Assay Kit (640175, BD
Biosciences) in 96- or 384-well (in the case of analogue
compound analyses) black plates. At 2 days postseeding, Ca2+
assessment during SOCE was performed as described
previously.24 Cells were treated with IA65 at different
concentrations for 15 min prior to SOCE measurement.
Concentrations of IA65 were maintained during SOCE
assessment. Data were analyzed using ScreenWorks Software
(v2.0.0.27, Molecular Devices). Response over baseline was
used as a relative measure of [Ca2+]CYT. Original IA65 and its
analogues were purchased from Chembridge Corporation (San
Diego, CA). For subsequent studies, IA65 was synthesized (as
described above: “Chemicals and Synthesis of the Orai1
Enhancer 4-((5-Phenyl-4-(trifluoromethyl)thiazol-2-yl)-
amino)benzoic acid (IA65)”) and was reconfirmed for its
activity.
Patch Clamp Electrophysiology. Cells were seeded onto
30 mm glass coverslips in the 6-well plates 24 h before
recordings. Whole-cell patch clamp electrophysiological
recordings were carried out using an Axopatch 200B and
Digidata 1440A (Molecular Devices, San Jose, CA). Pipettes
were pulled from borosilicate glass capillaries (World Precision
Instruments) with a P-1000 Flaming/Brown micropipette
puller (Sutter Instrument Company, Novato, CA) and
polished using DMF1000 (World Precision Instruments,
Sarasota, FL). Resistances of filled pipettes were 2−4 MΩ.
Under whole-cell configuration, only cells with series
resistances less than 8 MΩ and tight seals (>16 gigohms)
were chosen to perform recordings. MgCl2 (8 mM) was
included in the pipet solution to inhibit TRPM7 currents.
Clampfit 10.3 software (Molecular Devices, San Jose, CA) was
used for data analysis.
For CRAC Current Recordings. We used Orai1/2/3 triple-
knockout HEK293 cells transfected with 4.0 μg of a plasmid
encoding eYFP-STIM1 and 1.0 μg of a plasmid encoding
either CFP-Orai1 or CFP-Orai3. In some CRAC recording
experiments, we used HEK293 cells stably expressing eYFP-
STIM1 and CFP-Orai1. Immediately after break-in, cells were
maintained at a +30 mV holding potential during experiments
Table 1. Quantitative PCR Primers
primers forward reverse
GAPDH (real-time PCR) 5′-CCCTTCATTGACCTCAACTACA-3′ 5′-ATGACAAGCTTCCCGTTCTC-3′
NONO (real-time PCR) 5′-TCCGAGGAGATACCAGTCGG-3′ 5′-CCTGGGCCTCTCAACTTCGAT-3′
ORAI2 (real-time PCR) 5′-TGGCGGAAGCTCTACCTGAG-3′ 5′-CGGGTACTGGTACTGCGTC-3′
ORAI3 (real-time PCR) 5′-CTGGAGAGTGACCACGAGTA-3′ 5′-TGGAGACCATGAGTGCAAAG-3′
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and subjected to a 250 ms voltage ramps from +100 to −140
mV every 2 s until CRAC currents reached steady-state level.
Bath solution: 115 mM Na-methanesulfonate, 10 mM CsCl,
1.2 mM MgSO4, 10 mM Hepes, 20 mM CaCl2, and 10 mM
glucose (pH 7.4 with NaOH). Two different pipet solutions,
containing either BAPTA or EGTA as buffer, were used and
showed comparable results: Pipette solution 1: 135 mM Cs-
methanesulfonate, 10 mM EGTA, 8 mM MgCl2, and 10 mM
Hepes (pH 7.2 with CsOH). Pipette solution 2: 115 mM Cs-
methanesulfonate, 20 mM Cs-BAPTA, 8 mM MgCl2, and 10
mM Hepes (pH adjusted to 7.2 with CsOH).
For CDI Data Collection. We used Orai1/2/3 triple-
knockout HEK293 cells transfected with 4.0 μg of a plasmid
encoding eYFP-STIM1 and 1.0 μg of a plasmid encoding
either CFP-Orai1, or CFP-Orai3. Immediately after break-in
and before CRAC currents have developed, we ran a stimulus
protocol consisting of families of 150 ms voltage steps (from
+30 mV holding potential to −120, −100, −80, and −60 mV).
A 2 s interval was applied between steps. At the beginning of
each pulse, a 2.5 ms voltage step to 0 mV was used to eliminate
residual capacitive artifacts from cell capacitance. This first
voltage step recording was used for leak subtraction. Next, a
250 ms voltage ramp from +100 to −140 mV was administered
every 2 s until CRAC currents reached steady-state level
(usually within 150−300 s). Once steady-state CRAC current
activation was achieved, CDI was determined by performing a
second round of voltage steps, using the same protocol used
during the first round described above. CDI was quantified as
the remaining current measured at 146 ms from the peak
current at the beginning of the pulse. Bath solution: 115 mM
Na-methanesulfonate, 10 mM CsCl, 1.2 mM MgSO4, 10 mM
Hepes, 20 mM CaCl2, and 10 mM glucose (pH 7.4 with
NaOH). Pipette solution: 135 mM Cs-methanesulfonate, 10
mM EGTA, 8 mM MgCl2, and 10 mM Hepes (pH 7.2 with
CsOH).
VSMC Proliferation and Migration Assays. VSMC
proliferation was measured using the CyQUANT Cell
Proliferation Assay (ThermoFisher Scientific, Waltham, MA).
VSMCs were initially trypsinized, washed in PBS, and
resuspended in 0.4% FBS culture media. Within the 0.4%
FBS culture media, VSMCs were treated with recombinant rat
PDGF-BB (R&D Systems, Minneapolis, MN) at a submaximal
concentration of 0.5 ng/mL or a maximal concentration of 10
ng/mL, along with 3 or 0.5 μM IA65 or vehicle control.
VSMCs were seeded at 3000 cells/well in a 96-well plate. In
order to measure initial seeding density, VSMCs were allowed
to attach for 3 h, and three wells from each condition were
washed with PBS and stained with the CyQUANT dye for 1 h
at 37 °C, 5% CO2, and 100% humidity. Fluorescence at 485
nm excitation and 530 nm emission was then measured using a
plate reader (Flexstation 3). Background fluorescence was
subtracted from each well. VSMCs were then returned to 37
°C, 5% CO2, and 100% humidity, and subsequent readings
were taken at 24, 48, and 72 h. Each fluorescent reading was
normalized to reading at 0 h and reported as RFU/RFU0.
To measure VSMC migration, 30 000 cells were seeded into
silicon inserts with a 500 μm gap in a 6-well plate in culture
media. After a monolayer of cells is formed in 24 h, culture
media is removed and replaced with 0.4% FBS culture media
to synchronize cells for an additional 24 h. Silicon inserts were
then removed, and VSMCs were washed with PBS. VSMCs
were then treated with 0.5 or 10 ng/mL recombinant rat
PDGF-BB (R&D Systems, Minneapolis, MN) along with 0.5
μM IA65 or vehicle control within 0.4% FBS culture media
supplemented with 10 μg/mL mitomycin C to inhibit
proliferation (Sigma-Aldrich, St. Louis, MO). Bright-field
images of the gap between the VSMC monolayers were
taken at 0 and 12 h. Percent of gap closure was measured from
subtracting the difference in gap area between 0 and 12 h using
ImageJ and then normalizing this difference to the area at 0 h.
Muscle Preparation for Single Fiber Imaging. In this
study we used mechanically skinned fibers to assess the
influence of IA65 on t-system Ca2+ handling in muscle fibers.33
This procedure involves physically peeling off the outer plasma
membrane (sarcolemma) of the muscle fiber, which leaves the
t-system, the invagination of the plasma membrane inside the
fiber. Bathing the mechanically skinned fiber in the solution
that mimics the normal cytoplasmic environment causes the t-
system to re-establish a normal membrane potential. Addi-
tionally, the contractile proteins and membranes remain fully
functional in regards to each of the steps in excitation−
contraction coupling and SOCE.34,47,48
All experimental methods using rodents were approved by
the Animal Ethics Committees at The University of Queens-
land. Male Wistar rat (6−9 weeks old) were killed by
asphyxiation via CO2 exposure, and the extensor digitorum
longus (EDL) muscles were rapidly excised. Muscles were then
placed in a Petri dish under paraffin oil above a layer of
Sylgard. Rhod-5N salt was trapped in the sealed t-system as
originally described by Lamb et al.49 Briefly, small bundles of
fibers from EDL muscles were isolated using fine forceps and
exposed to a Na+-based physiological solution (external
solution) containing the following: Rhod 5N 2.5 mM;
CaCl2, 2.5 mM; NaCl, 132 mM; MgCl2, 1 mM; KCl, 3.3
mM; Hepes, 20 mM. The pH was adjusted to 7.4 with NaOH.
The dye was allowed to diffuse for 10 min or more into the t-
system from the surrounding bubble of solution containing
fluorescent dye. After this equilibration period, individual fibers
that had been exposed to the dye solution were isolated from
the bundle and mechanically skinned. After skinning, fibers
were transferred to an experimental chamber containing a K+-
based internal solution which allowed the sealed t-system to
generate a normal resting membrane potential.50,51 The
solution contained Mg2+, 1 mM; CaEGTA/EGTA, 50;
Hepes, 10 mM; K+, 103−106 mM; Na+, 36 mM; ATP, 8
mM; creatine phosphate, 10 mM; and N-benzyl-p-toluene-
sulfonamide (BTS), 0.05 mM with pH adjusted (with KOH)
to 7.1. Osmolality was adjust to 290 ± 10 mOsm/kg with
sucrose. Free [Ca2+] was set to 0 or 200 nM in this solution.
To release SR Ca2+, a similar solution with 30 mM caffeine,
[Mg2+] lowered to 0.01 mM, and no added Ca2+ was applied to
the skinned fibers.34 To make the RyRs leaky without
triggering a release of Ca2+ from the SR, [Mg2+]cyto was
lowered to 0.4 mM.33
Confocal Imaging. Mounted skinned fibers were imaged
using an Olympus FV1000 confocal microscope equipped with
an Olympus 0.9NA 40× Plan-Apochromat objective. Rhod-5N
was excited with a 543 nm HeNe laser, and the emission was
filtered using the Olympus spectra detector. For tracking Ca2+
movements across the t-system membrane, images were
continuously recorded in xyt mode with an aspect ratio of
256 × 512, with the long aspect of the image parallel with that
of the preparation. Temporal resolution of imaging in this
mode where the fluorescence signal from within the borders of
the fiber was 0.8 s.
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Image Analysis for Ca2+ Measurements. The fluorescence
of t-system rhod-5N [(t) (F(t)] was collected during
continuous xyt imaging during multiple internal solution
changes. At the end of the experiment, each fiber was exposed
to ionophore and 5 mM Ca2+, followed by 0 Ca2+ to obtain the
fluorescence maximum (Fmax) and minimum (Fmin), respec-
tively. These values were used in conjunction with the
previously determined KD of rhod-5N in the t-system of 0.8
mM34 to determine [Ca2+]t‑sys, with the relationship: [Ca
2+]t‑sys
(t) = KD,Ca × (F(t) − Fmin)/(Fmax − F(t)).
Selectivity Screen. A selectivity screen was conducted to
assess the activity of IA65 against TRPV1, TRPM8, and
CaV2.2. TRPV1 and TRPM8 assessments were performed in
HEK293 cells overexpressing TRPV1 or TRPM8, and CaV2.2
assessment was conducted in SH-SY5Y neuroblastoma cells in
the presence of nifedipine (10 μM), as previously described.24
FLIPRTETRA and ScreenWorks 3.2 software were used for
acquiring and analyzing data.
Statistical Analysis. Data were statistically analyzed using
GraphPad Prism Software (La Jolla, CA). Specific statistical
tests used for each experiment are described in figure captions.
A p-value of less than 0.05 is considered statistically significant.
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